Skip to main content
. Author manuscript; available in PMC: 2017 Apr 1.
Published in final edited form as: Lancet Oncol. 2016 Mar 11;17(4):452–463. doi: 10.1016/S1470-2045(15)00614-2

Figure 3. Exposure and response to ceritinib.

Figure 3

Duration of exposure and response to ceritinib in patients with ALK-rearranged NSCLC with brain metastases at baseline by MRI/CT (retrospective, independent readings; n=94). Whether or not the patient received prior radiotherapy to the brain is indicated on the plots; in patients who did received prior radiotherapy, the duration between last radiotherapy treatment and start of ceritinib treatment (≥ or < than 3 months) is also indicated.

ALK=anaplastic lymphoma kinase. BIOR=best intracranial overall response. CR=complete response. NCRNPD=non-complete response non-progressive disease. NSCLC=non-small cell lung cancer. PD=progressive disease. PR=partial response. RT=radiotherapy. SD=stable disease. UNK=unknown.